| Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ... Journal of Clinical Oncology 35 (14), 1542-1549, 2017 | 703 | 2017 |
| Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ... Journal of Clinical Oncology 39 (30), 3391-3402, 2021 | 557 | 2021 |
| Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer SJ Bagley, S Kothari, C Aggarwal, JM Bauml, EW Alley, TL Evans, ... Lung cancer 106, 1-7, 2017 | 499 | 2017 |
| Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer C Aggarwal, JC Thompson, TA Black, SI Katz, R Fan, SS Yee, AL Chien, ... JAMA oncology 5 (2), 173-180, 2019 | 461 | 2019 |
| Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA JC Thompson, SS Yee, AB Troxel, SL Savitch, R Fan, D Balli, ... Clinical Cancer Research 22 (23), 5772-5782, 2016 | 377 | 2016 |
| Pembrolizumab after completion of locally ablative therapy for oligometastatic non–small cell lung cancer: a phase 2 trial JM Bauml, R Mick, C Ciunci, C Aggarwal, C Davis, T Evans, ... JAMA oncology 5 (9), 1283-1290, 2019 | 282 | 2019 |
| Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 … A Passaro, J Wang, Y Wang, SH Lee, B Melosky, JY Shih, K Azuma, ... Annals of Oncology 35 (1), 77-90, 2024 | 176 | 2024 |
| A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery … S Swisher-McClure, JN Lukens, C Aggarwal, P Ahn, D Basu, JM Bauml, ... International Journal of Radiation Oncology* Biology* Physics 106 (4), 725-732, 2020 | 152 | 2020 |
| Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer C Aggarwal, RB Cohen, MP Morrow, KA Kraynyak, AJ Sylvester, ... Clinical Cancer Research 25 (1), 110-124, 2019 | 142 | 2019 |
| Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck JM Bauml, R Vinnakota, YH Anna Park, SE Bates, T Fojo, C Aggarwal, ... JNCI: Journal of the National Cancer Institute 111 (5), 490-497, 2019 | 112 | 2019 |
| JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). EB Haura, BC Cho, JS Lee, JY Han, KH Lee, RE Sanborn, R Govindan, ... Journal of Clinical Oncology 37 (15_suppl), 9009-9009, 2019 | 110 | 2019 |
| Radiologic pseudoprogression during anti–PD-1 therapy for advanced non–small cell lung cancer SI Katz, M Hammer, SJ Bagley, C Aggarwal, JM Bauml, JC Thompson, ... Journal of Thoracic Oncology 13 (7), 978-986, 2018 | 105 | 2018 |
| Scan-associated distress in lung cancer: quantifying the impact of “scanxiety” JM Bauml, A Troxel, CN Epperson, RB Cohen, K Schmitz, C Stricker, ... Lung Cancer 100, 110-113, 2016 | 104 | 2016 |
| Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross‐sectional survey JM Bauml, S Chokshi, MM Schapira, EO Im, SQ Li, CJ Langer, SA Ibrahim, ... Cancer 121 (14), 2431-2438, 2015 | 104 | 2015 |
| A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours A Maity, R Mick, AC Huang, SM George, MD Farwell, JN Lukens, ... British journal of cancer 119 (10), 1200-1207, 2018 | 103 | 2018 |
| Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? J Bauml, R Mick, Y Zhang, CD Watt, A Vachani, C Aggarwal, T Evans, ... Lung cancer 81 (3), 347-353, 2013 | 102 | 2013 |
| Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non–small cell lung cancer C Aggarwal, JC Thompson, AL Chien, KJ Quinn, WT Hwang, TA Black, ... Clinical Cancer Research 26 (10), 2354-2361, 2020 | 97 | 2020 |
| Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential … J Bauml, BC Cho, K Park, KH Lee, EUNK Cho, DW Kim, SW Kim, ... Journal of Clinical Oncology 39 (15_suppl), 9006-9006, 2021 | 89 | 2021 |
| Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer C Aggarwal, CW Davis, R Mick, JC Thompson, S Ahmed, S Jeffries, ... JCO precision oncology 2, 1-29, 2018 | 87 | 2018 |
| Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non–Small-Cell Lung … E Bange, ME Marmarelis, WT Hwang, YX Yang, JC Thompson, ... JCO precision oncology 3, 1-11, 2019 | 81 | 2019 |
